Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
216.91 USD | +1.31% | +2.31% | +5.87% |
Dec. 01 | Will Powell deliver an early Christmas present? | ![]() |
Dec. 01 | ANALYST RECOMMENDATIONS : Abbvie, Boeing, IBM, Lululemon Athletica, Meta Platforms... | ![]() |
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows:
- development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;
- development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;
- integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.
Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Calendar
2024-02-13
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy

Mean consensus
BUY
Number of Analysts
21
Last Close Price
216.91USD
Average target price
229.52USD
Spread / Average Target
+5.81%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.87% | 39 586 M $ | |
+65.53% | 40 132 M $ | |
-55.56% | 30 438 M $ | |
-26.11% | 28 571 M $ | |
+38.66% | 22 175 M $ | |
-27.87% | 21 511 M $ | |
+1.62% | 17 412 M $ | |
-13.43% | 11 313 M $ | |
-7.44% | 10 346 M $ | |
-22.09% | 10 212 M $ |
- Stock
- Equities
- Stock Iqvia Holdings Inc. - Nyse
- News Iqvia Holdings Inc.
- UBS Adjusts IQVIA Price Target to $265 From $285, Maintains Buy Rating